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Extremely low concentrations of high density lipoprotein (HDL)-cholesterol and apolipoprotein (apo) AI are features of Tangier disease
caused by autosomal recessive mutations in ATP-binding cassette transporter A1 (ABCA1). Less deleterious, but dominantly inherited
mutations cause HDL deficiency. We investigated causes of severe HDL deficiency in a 42-year-old female with progressive coronary disease.
ApoAI-mediated efflux of cholesterol from the proband’s fibroblasts was less than 10% of normal and nucleotide sequencing revealed
inheritance of two novel mutations in ABCAI, V1704D and L1379F. ABCA1 mRNAwas approximately 3-fold higher in the proband’s cells
than in control cells; preincubation with cholesterol increased it 5-fold in control and 8-fold in the proband’s cells, but similar amounts of
ABCA1 protein were present in control and mutant cells. When transiently transfected into HEK293 cells, confocal microscopy revealed that
both mutant proteins were retained in the endoplasmic reticulum, while wild-type ABCA1 was located at the plasma membrane.
Severe HDL deficiency in the proband was caused by two novel autosomal recessive mutations in ABCA1, one (V1704D) predicted to lie in
a transmembrane segment and the other (L1379F) in a large extracellular loop. Both mutations prevent normal trafficking of ABCA1, thereby
explaining their inability to mediate apoA1-dependent lipid efflux.
D 2004 Elsevier B.V. All rights reserved.Keywords: ABCA1; Protein trafficking; HDL deficiency; Apolipoprotein AI; Cholesterol efflux
1. Introduction flux from cells [6–12], and these patients invariably haveTangier disease [1–4] is a rare autosomal recessive
disorder characterised by extremely low levels of high
density lipoprotein (HDL)-cholesterol and of apolipoprotein
(apo) AI in plasma, and by the accumulation of cholesterol
in macrophage-rich tissues, notably the tonsils, which ac-
quire a characteristic orange-yellow colour. Hepatospleno-
megaly and peripheral neuropathy are also commonly
associated with this disorder [5]. Tangier disease is caused
by mutations in the ATP-binding cassette transporter A1
(ABCA1) gene that impair apoAI-mediated cholesterol ef-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.01.007
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E-mail address: anne.soutar@csc.mrc.ac.uk (A.K. Soutar).defects in both alleles of ABCA1. Some heterozygous
relatives of Tangier patients display an intermediate pheno-
type of low to normal HDL-cholesterol and a 50% reduction
in apoAI-mediated efflux of cholesterol [13]. In the absence
of functional ABCA1 protein, newly secreted apoAI is
rapidly degraded and cholesterol efflux deficiency ensues
[14]. The disorder is often, but not always, associated with
an increased risk of coronary artery disease [5].
Familial HDL deficiency is characterised by less severe
HDL deficiency than that seen in Tangier disease, but with a
dominant mode of inheritance. Nevertheless, it too results
from mutations in ABCA1 [12]. As yet, no clear distinction
has emerged between the mutations in ABCA1 that result in
autosomal recessive Tangier disease and those that cause
dominant HDL deficiency, or between those that do or do
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of cholesterol in the reticuloendothelial system. In this
study, we describe a patient who has inherited two defective
alleles of ABCA1 from apparently unaffected parents, each
encoding a previously undescribed single amino acid sub-
stitution (L1379F and V1704D). The patient has almost
complete HDL deficiency and severe premature coronary
artery disease, but does not have yellow tonsils or other
overt signs of cholesterol deposition in macrophages.2. Materials and methods
2.1. Patient and family studies
The proband was a 42-year-old pre-menopausal woman of
English origin who was assessed in the lipid clinic at Chelsea
and Westminster Hospital, London after diagnosis of coro-
nary artery disease treated by coronary artery bypass graft.
Family members were evaluated separately, with informed
consent.
All blood samples for lipid and lipoprotein analysis were
taken after an overnight fast of at least 10 h. Low density
lipoprotein cholesterol (LDL)-cholesterol concentrations
were calculated using the Friedwald formula [15]. ApoAI
and apolipoprotein B were measured by nephelometry. A
skin biopsy was taken aseptically under local anaesthesia
with informed consent from the proband. Dermal fibroblasts
were grown from 0.25 cm2 explants of dermis cultured in
Dulbecco’s modified Eagles medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum, 2 mmol/l gluta-
mine, 100 units penicillin/ml and 100 Ag streptomycin/ml.
2.2. Measurement of LCAT activity
Plasma LCAT activity was measured using the egg
lecithin:human apoAI: [3H]-cholesterol proteoliposome sub-
strate method as described previously [16]. This assay
largely reflects LCAT concentration and was carried out
by incubating plasma (7.5 Al) with substrate (242.5 Al) at
37 jC for 1 h. Lipids were extracted by addition of
chloroform–methanol and separated by thin-layer chroma-
tography; radioactivity in the free cholesterol and choles-
teryl ester bands was measured and the values used to
calculate the percentage of cholesterol esterified per hour.
2.3. Agarose gel electrophoresis and immunoblotting
Lipoproteins in plasma (2 Al) were separated by electro-
phoresis on pre-cast agarose gels (Hydragel, Sebia) and either
stained with Sudan black or transferred onto Hybond-ECL
nitrocellulose membranes (Amersham Pharmacia) by pres-
sure blotting. For immunostaining, monoclonal antibodies
against human apoAI (Calbiochem) or LCAT (S. Schepel-
mann and J.S. Owen, unpublished data) were diluted 1:1000
in 3% (w/v) bovine serum albumin in phosphate-bufferedsaline (PBS). A goat anti-mouse Ig-HRP (Amersham Phar-
macia) was used as a secondary antibody (1:5000 in 10% (w/
v) milk powder/PBS-Tween), followed by detection by
enhanced chemiluminescence (Amersham Pharmacia).
2.4. Measurement of cholesterol efflux
Control and proband skin fibroblasts were grown to 50–
70% confluence in 12-well tissue culture plates. Cells were
labeled by incubation with 1 ACi/ml [3H]-cholesterol in
DMEM containing 5% fetal bovine serum for 72 h. The
monolayers were washed and incubated with BSA (1 mg/
ml) in serum-free DMEM for 48 h to allow the labeled
cholesterol to equilibrate with intracellular cholesterol
pools. Cholesterol efflux was induced by the addition of 5
Ag/ml human apoAI [17] in serum-free DMEM to quadru-
plicate wells; control wells received DMEM alone. Media
were removed after 6 h, the cells washed once with PBS and
then dissolved in 0.1 M NaOH. Radioactivity in media and
cells were measured and the cholesterol efflux rate calcu-
lated as the % of dpm in medium/(dpm in medium+ dpm in
cells). The mean of values for patient’s cells (apoAI-medi-
ated efflux minus mean of unstimulated cells) was compared
to the value for control cells (apoAI-mediated efflux minus
mean of unstimulated cells) by an unpaired Student’s t-test.
2.5. Nucleotide sequence analysis
DNA was extracted from venous whole blood [18].
Genotyping was as previously described [19] with markers
from the ABI Prism linkage mapping set (PE Applied
Biosystems). The coding regions and proximal promoter
(starting from 395 bp upstream from the ATG of ABCA1)
were amplified by PCR with primers located within 50–70
bp of each splice junction (primer details available on request:
c.albrecht@csc.mrc.ac.uk). PCR reactions were carried out in
a volume of 25 Al containing 100 ng of DNA, 250 nM of each
primer, 200 AM of each dNTP, 1 Thermopol buffer (New
England Biolabs, Hitchen, Herts, UK) and 1 U of Vent
polymerase (New England Biolabs). Amplification condi-
tions were as follows: initial denaturation for 1 min at 97 jC,
35 cycles of 1min at 96 jC, 1min at 52–59 jC (depending on
the primer pair) and 1 min at 72 jC, with a final extension at
72 jC for 10 min. Amplification products were analysed on
2% low melting agarose gels, purified from the gel with a gel
extraction kit (Qiagen) and sequenced with both PCR primers
using an ABI 3700 Prism automated sequencer. Sequences
were analysed with Sequence Navigator software, and com-
pared with the published sequence of ABCA1 cDNA (Gen-
Bank accession no: AF285167). ABCA1 mRNA was
sequenced after amplification by RT-PCR from total RNA,
isolated from cultured skin fibroblasts using RNA-Beek
RNA isolation reagent according to the manufacturer’s
instructions (Biogenesis Ltd.). The RT reaction comprised
0.04 U of oligo-p(dT)15 primer, 5 mMMgCl2, 1 mM of each
dNTP, 40 U RNAse inhibitor, 1 reaction buffer (Roche)
C. Albrecht et al. / Biochimica et Biophysica Acta 1689 (2004) 47–57 49and 20 U AMV reverse transcriptase (Roche). RT reaction
mix (1–5 Al) was then used as template in a PCR reaction as
described above, with primers that produced nine overlap-
ping fragments of the coding regions (details available on
request).
2.6. Analysis of polymorphisms in DNA by WAVEk
analysis
PCR fragments of ABCA1 exons 28, 36 and 6 were
amplified as described above with the following primers:exon 28, 5V-TCTAACACTTGCCGTTTCCTGCTGTC and
5V-CCTCGTAAACATCTTTGGTCTGCTCG
exon 36, 5V-TTGTCTGTGTGTCCATGTCCTCACTG and
5V-GCTGGAACATTTCCTGATGATAGCCAG
exon 6, 5V-GGACCCAGCTTCCAATCTTCATAATCC and
5V-GCCTCACATTCCGAAAGCATTAGTGCPCR products (8 Al of reaction mix) were denatured by
heating to 94 jC, followed by cooling to 25 jC over 25 min
to enhance heteroduplex formation, and analysed on a
WAVEk Nucleic Acid Fragment Analysis System (Trans-
genomic). The optimum temperatures for analysis of each
fragment were predicted with Wavemaker software (Trans-
genomic) and confirmed empirically.
2.7. Quantification of mRNA
Skin fibroblasts were preincubated for 24 h in DMEM
medium containing either 10% fetal bovine serum or cho-
lesterol (30 Ag/ml) complexed to fatty acid-free bovine
serum albumin (2% w/v). Cell monolayers from two 9-cm
dishes were washed twice with sterile Puck’s saline A
(Gibco BRL, Life Technologies), scraped into a sterile 50
ml tube in 5 ml of Puck’s saline and pelleted by centrifu-
gation for 10 min at 3000 rpm. Total cellular RNA was
extracted as described above. Contaminating DNA was
removed by incubation of total RNA with DNAse I (Prom-
ega). For cDNA synthesis, RNA (1 Ag) was transcribed with
a First Strand cDNA synthesis Kit for RT-PCR (Roche),
according to the supplier’s instructions. For Taqman analy-
sis, the cDNA was diluted 20-fold with nuclease-free water.
Primers and probe for Taqman analysis of ABCA1
mRNA were designed with PrimerExpress software (PE
Applied Biosystems) and the reaction optimised according
to PE User bulletin number 2. The forward primer was 5V-
GGGAGGCTCCCGGAGTT in exon 3, the reverse primer
was 5V-GTATAAAAGAAGCCTCCGAGCATC in exon 4,
and the FAM-labeled probe, spanning exons 3 and 4, was 5V-
AACTTTAACAAATCCATTGTGGCTCGCCTGT. Single
tube Taqman analysis was performed on an ABI prism
7700 sequence detection system with 300 nM of forward
and reverse primers in the presence of 200 nM 5VFAM-3
TAMRA-tagged probe. The internal standard was GAPDH
mRNA, assayed with commercially supplied reagents (PE
Applied Biosystems). Reactions were carried out in tripli-cate and contained 5 Al of diluted cDNA in a total volume of
25 Al. The amount of ABCA1 mRNA in cells was expressed
relative to that of GAPDH, and was calculated as 2-DCt,
where DCt = CttargetCtGAPDH. Fold induction (relative
expression in patient/relative expression in control) was
expressed as 2-DDCt where DDCt =DCtpatientDCtcontrol.
2.8. Immunoblotting of ABCA1 protein in cell membranes
Skin fibroblasts were preincubated in medium containing
either 10% fetal bovine serum or 2% bovine serum albumin
plus 30 Ag/ml cholesterol for 24 h [11]. Cells in two 9-cm
dishes were washed twice with PBS and harvested by
scraping from the dish. A total membrane fraction was
prepared as described by Rosenberg et al. [20]. Briefly,
the cells were lysed by homogenisation in 1 ml ice-cold
buffer A (50 mM maltose, 50 mM Tris–HCl pH 7.5, 2 mM
EGTA, 2 mg/ml aprotinin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM benzamidine). Cell debris was removed by
centrifugation at 500 g for 10 min, the supernatant diluted
3-fold with buffer B (buffer A with 300 mM maltose), and
the membrane fraction pelleted by centrifugation at
100,000 g for 60 min. The membrane pellet was resus-
pended in 100 Al buffer B and protein content measured
(Biorad protein assay). Membrane proteins were fractionat-
ed on reduced SDS-PAGE (12% acrylamide) and transferred
to nitrocellulose membranes. ABCA1 protein was detected
with a rabbit antipeptide antiserum, diluted 1:1500 (Abcam
Ltd., Cambridge, UK) followed by peroxidase-labeled anti
rabbit IgG, diluted 1:3000 (Dako).
2.9. Plasmids/DNA construction
Full-length human ABCA1 cDNA was generated by
reverse transcriptase PCR of mRNA obtained from skin
fibroblasts of the patient and a healthy individual (see
Nucleotide sequence analysis). Wild-type ABCA1 cDNA
was cloned into pGEMR-11Zf vector (Promega) and
replaced with the corresponding DNA fragment (Asp718–
BamHI) containing each mutation (4425 or 5401). En-
hanced green fluorescent protein (eGFP) was fused in frame
to the C-terminus of ABCA1 by overlapping PCR strategy
as described previously [21] using the following primers:
5V-CCAGAGGAGATGCTTTCCTTAA/5V-CTTGCTCAC-
CATTACATAGCTTTC for ABCA1 and 5V-GAAAGC-
TATGTAATGGTGAGCAAG/5V-TCTTTGTCGCGGCCG-
CTTTACTTGTACAGCTCGTCCATGCC (including a NotI
restriction site) for eGFP. The PCR reactions were carried out
with 100 ng DNA as described above (see Nucleotide
sequence analysis) at an annealing temperature of 55 jC.
The gel purified PCR products were pooled and 1
Al subjected to another PCR reaction with the outermost
primers (annealing temperature 55 jC, extension 1.5 min at
72 jC, min). The PCR product was cloned into pCRR
4Blunt-TOPO vector (Invitrogen) and BamHI–NotI ABCA1
cDNA fragments in the pGEMR-11Zf constructs replaced
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mutant ABCA1-eGFP cDNAs were cloned with SalI–NotI
into pCI-neo mammalian expression vector (Promega) and
all constructs verified by complete sequencing.
2.10. Analysis of expression of ABCA1 eGFP fusion
proteins in HEK 293 cells
HEK 293 cells were plated on poly-L-lysine (Sigma)
coated glass cover slips in six-well plates 12 h before
transfection. Cells were transfected with plasmids containing
wild-type or mutated ABCA1-eGFP cDNA according to the
calcium phosphate transfection protocol (Clontech) with 2
Ag of DNA/well, washed twice with PBS after 6 h, and fixed
in 4% formaldehyde/4% sucrose 24 h after transfection.
Fixed cells were permeabilised with 0.1% Triton X-100
for 4 min and stained with DAPI (15 mg/ml; 1:10,000
dilution; Molecular Probes) for nuclear DNA. In order to
identify the intracellular localisation of the wild-type and
mutant ABCA1 proteins, cells were also stained with the
mouse monoclonal antibody against sarco/endoplasmic re-
ticulum calcium ATPase (SERCA 2; clone 11D8; Affinity
Bioreagents Inc.) for 2 h at room temperature after blocking
with 0.2% fish skin gelatin in PBS. The antibody against
SERCA2 was detected by a goat anti mouse IgG secondary
antibody conjugated to Alexa 568 (Molecular Probes, 1:400
dilution for 30 min, room temperature).Fig. 1. Pedigree of the HDL-deficient proband. The proband is indicated with an
(mmol/l) and the centile in England according to age and gender [22]. Markers tha
bp  10 6; ABCA1 is at f 101.15 (UCSC genome browser, http:// genome.ucsc
brackets were deduced). A recombination in the maternal allele of the proband’s u
box) carried the L1379F variant of ABCA1, and the maternal allele (shaded box)Cells were imaged by a Leica SP confocal microscope
through a 63X 1.32 NA PlanApoChromat oil immersion
objective. eGFP was excited by a 488 nm line of an Argon
laser and Alexa 568 by a 568 nm line of a Krypton laser. In
order to avoid bleedthrough, the fluorophores were excited
sequentially. The emitted fluorescence was collected sepa-
rately through a triple dichroic mirror 488/568/663. The
emission filter bands for eGFP and Alexa 568 fluorescence
were restricted to 500–552 nm and 594–620 nm, respec-
tively. DAPI staining of nuclear DNA was excited by a 351
nm line of a UV laser and emission fluorescence collected
by a 396–508 nm bandpass filter.
Stack of confocal sections separated by 1 Am increments
were taken and images analysed by Metamorph software
(Universal Imaging Corporation, USA).3. Results
3.1. Clinical findings
The 42-year-old proband presented with progressive and
premature coronary artery disease requiring coronary artery
bypass surgery; at 1 year follow-up, angiography confirmed
severe progressive coronary atheroma. The proband’s fasting
lipid profile revealed marked HDL deficiency, with HDL-
cholesterol less than 0.1 mmol/l; total cholesterol was 3.8arrow; values below each symbol indicate HDL-cholesterol concentration
t flank ABCA1 on chromosome 9q31 [26] are shown with their position in
.edu; April 2003 freeze). Genotypes are shown below each symbol (those in
naffected brother is indicated ( ). In the proband, the paternal allele (clear
carried the V1704D variant.
Fig. 2. Efflux of cholesterol from skin fibroblasts in culture. Skin fibroblasts
were equilibrated with [3H]-cholesterol and incubated in serum-free
medium with or without human apoA1 (5 Ag/ml). Cholesterol efflux was
measured as the percentage of labeled cholesterol present in the medium
after 6 h. The mean of values from three separate determinations is shown.
The significance of the difference between proband and control was
determined by unpaired Student’s t-test.
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cholesterol was 2.8 mmol/l. Lipoprotein analysis showed
apoAI was < 0.3 g/l, apoB 0.83 g/l and Lp(a) 98 mg/l. Apart
from HDL deficiency, no other risk factors for premature
coronary disease were identified in the proband, except that
she had been a modest cigarette smoker (10 per day).
Although our study was focused on identifying the proband’s
clinical and biochemical phenotype, HDL-cholesterol levels
were also measured in her immediate family. For both
parents, her sister and her daughter aged 17 years these were
below the 10th centile for their age and gender [22] (Fig. 1).
The HDL-cholesterol of her 15-year-old son was just above
the 10th centile for 16–24-year-olds, whereas that of her
brother was close to the mean for his age and gender. The
proband’s father had coronary heart disease, but had only
become symptomatic at age 70 years and her mother was
well at age 79 years. On physical examination, the proband
did not have enlarged yellow tonsils, hepatosplenomegaly or
peripheral neuropathy; renal function was normal. PossibleTable 1
Genetic variants in ABCA1 in the HDL-deficient proband
Exon Base no.a Codonb Base su
1 273 hmz C
2 368–370 Leu 26 hmz TT
5 764 Leu 158 (98) htz A/G
6 947 Arg 219 (159) htz G/A
14 2330 Ile 680 (620) hmz C
16 2763 Ile 825 (765) hmz G
17 2930 Met 883 (823) hmz A
28 4425 Leu 1379 (1319) htz C/T
30 4571 Thr 1427 (1367) htz G/A
34 5050 Arg 1587 (1527) htz G/A
36 5401 Val 1704 (1644) htz T/A
a Based on published sequence for cDNA (GenBank accession AF285167).
b Based on ATG start codon = bp 291-3 in cDNA sequence above (previous cunderlying causes of apoAI or HDL deficiency were inves-
tigated, including LCAT deficiency [23] and mutations in the
genes encoding apoAI [23] or ABCA1 [9–12].
3.2. Investigation of inherited defects in LCAT or apoAI
Mutations in the genes for LCAT and apoAI were ex-
cluded as the cause of HDL deficiency. LCAT activity in the
proband’s plasma, as determined in a proteoliposomal assay
[16], was at the lower end of the normal range, with an
esterification rate of 8.5%/h, 67 nmol/ml/h (reference range
of 7.7–12.8%/h; 60–101 nmol/ml/h) [24]; 74% of plasma
cholesterol was esterified (reference range 68–75%) [24].
Immunoblotting of plasma proteins fractionated by agarose
gel electrophoresis revealed normal amounts of LCAT pro-
tein, but undetectable apoAI in the proband’s plasma. Anal-
ysis of the sequence of the apoAI gene in the proband’s DNA
[25] revealed no mutations in the coding sequence, intron/
exon splice junctions or proximal promoter.
3.3. Investigation of inherited defects in ABCA1 as the
cause of HDL deficiency
There was no difference in the basal rate of cholesterol
efflux from the proband’s skin fibroblasts cultured in
serum-free medium compared to that in control fibroblasts
(1.5 vs. 1.2% of cellular free cholesterol in 6 h) (Fig. 2).
However, in the presence of apoAI, efflux from the
proband’s cells barely increased over the basal level,
whereas efflux from control cells was increased by approx.
6-fold to 7.0% of cellular free cholesterol, a value consis-
tent with other studies [11]. This marked reduction of
apoAI-mediated cholesterol efflux from the proband’s
fibroblast (< 10% of normal) suggests defective ABCA1
activity in her cells. Analysis of markers flanking ABCA1
on chromosome 9q31 [26] revealed that the proband had
inherited two different alleles of ABCA1, and that neither
of her unaffected siblings had inherited the same two
alleles (Fig. 1).bstitution Amino acid change Comments
to G none common [27]
A to CTG none CTG in genomic
sequence [27]
none common [29]
Arg to Lys common [28]
none common [28]
Ile to Val common [28]
Met to Ile common [28]
Leu to Phe novel, rare
none common [28]
Arg to Lys common [28]
Val to Asp novel, rare
odon no. in parentheses).
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cause of the apoAI deficiency, and hence the nucleotide
sequence of the gene was determined. This revealed that the
proband was heterozygous at a number of sites in ABCA1,
as listed in Table 1. The majority of these were polymor-
phisms that have been observed in control populations [27–
29]. However, two single base pair substitutions were novel,
namely C4425T in exon 28 (based on GenBank accession no.
AF28517), predicted to substitute L1379 with Phe, and
T5401A in exon 36, predicted to substitute V1704 with
Asp. Neither of these variants was found in 164 alleles of
a control English population [30]. In comparison, the alleleFig. 3. Expression of ABCA1-eGFP fusion proteins in HEK 293 cells. (a) Confo
ABCA1-eGFP (left panel), ABCA1-eGFP L1379F (middle panel) and ABCA1-eG
staining of nuclear DNA in blue. Both mutations caused severe alteration in ABC
(b) HEK 293 cells expressing wild-type ABCA1-eGFP, ABCA1-eGFP L1379F
Confocal sections are shown for eGFP (green, left column), SERCA 2 (red, mid
(yellow, right column). A large extent of co-localisation was found for both mutant
type ABCA1 localised predominantly to the plasma membrane and no co-localisfrequency of the R219K polymorphism was 0.22 (K allele),
similar to that found in other European populations [31].
The proband’s father was heterozygous for L1379F, and her
mother and sister for the V1704D variant (Fig. 1).
3.4. Expression of normal and mutant ABCA1 in vitro
The L1379F and V1704D mutations were introduced
into the full-length cDNA for ABCA1, fused at its carboxy-
terminus to eGFP. The C-terminal eGFP tag does not alter
either the expression and function of the ABCA1 protein or
its localisation [32,33]. Both wild-type (WT) and mutantcal sections of transiently transfected HEK 293 cells expressing wild-type
FP V1704D (right panel); eGFP fluorescence is shown in green and DAPI
A1 trafficking to the plasma membrane as compared to the wild-type (WT).
and ABCA1-eGFP V1704D were stained for SERCA 2 as an ER marker.
dle column) and the co-localisation of eGFP and SERCA 2 in the overlay
s, suggesting retention of L1379F and V1704D in the ER. In contrast, wild-
ation with the ER marker was apparent. Dimension bar indicates 10 Am.
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transiently transfected HEK293 cells. As expected [32,33],
normal ABCA1-eGFP was present mainly at the cell surface
(Fig. 3a, left panel) with punctate intracellular vesicles
visible in some cells and possible accumulation in the Golgi
in others (data not shown). In marked contrast to this,
trafficking of both mutated proteins to the plasma membrane
was severely altered in comparison to the wild-type (Fig. 3a,
middle and right panels). Their intracellular localisation
pattern suggested that both were present largely in the
endoplasmic reticulum (ER). This was confirmed by the
observation that both mutant eGFP fusion proteins, but not
wild-type ABCA1-eGFP, co-localised extensively withFig. 4. Quantification of ABCA1 mRNA and protein in cultured skin
fibroblasts. (a) Total RNA was isolated from skin fibroblasts incubated for
24 h in medium containing 10% serum or in serum-free medium containing
2% BSA and 30 Ag/ml cholesterol. Basal ABCA1 mRNA levels in the
proband’s cells incubated with serum is expressed relative to the mean of
values (normalized to 1.0) from cells from four different normolipaemic
controls (left). Also shown is the effect of cholesterol loading on ABCA1
mRNA levels in control cells (mean of four, centre) and the proband’s cells
(right), relative to the value in cells incubated with serum. Each value
represents the meanF S.D. of two Taqman real-time PCR determinations of
at least three different preparations of RNA. The variation between control
cell lines was less than 10% of the mean for cells incubated in medium and
15% for cells incubated with cholesterol. Significant differences ( P values)
were determined by unpaired Student’s t-test. (b) Membrane proteins from
cultured fibroblasts (40 Ag in approx. 25 Al of extract) were fractionated by
reducing SDS-PAGE (12% acrylamide gels) and immunoblotted with rabbit
polyclonal anti-ABCA1 peptide. Bound antibody was detected with
peroxidase-conjugated anti-rabbit IgG by chemiluminescence (2 min
exposure). The positions of marker proteins (kDa) on the blot are indicated.sarco/endoplasmic reticulum calcium ATPase (SERCA 2),
a marker of the ER [34] (Fig. 3b).
3.5. ABCA1 expression in cultured skin fibroblasts
Cultured skin fibroblasts from the proband contained 3-
fold more ABCA1 mRNA relative to GAPDH mRNA than
control cells when assayed by real-time PCR (Fig. 4a). The
variation in ABCA1 mRNA content relative to GAPDH
mRNA in cultured skin fibroblasts from four different
control subjects was less than 10% (DCt = 6.84F 0.15).
When the cells were preincubated with cholesterol to induce
ABCA1 expression, the mean relative level of ABCA1
mRNA increased by approximately 6-fold in control cells
(DCt = 4.16F 0.27, n = 4), and more than 8-fold in the
proband’s cells (Fig. 4a). In contrast, there was no discern-
ible difference between the amount of ABCA1 protein in
membranes from the proband’s and control cells when
estimated by semi-quantitative immunoblotting (Fig. 4b).4. Discussion
We describe a patient of English origin with severe HDL
deficiency and premature coronary disease who is hetero-
zygous for two rare alleles of ABCA1 that are predicted to
cause single amino acid substitutions, L1379F and V1704D.
These mutant alleles have not been described previously
and, as far as we are aware, this is the first individual of
English origin known to have a disorder caused by muta-
tions in ABCA1. There is strong evidence that these muta-
tions in ABCA1 are the underlying cause of the HDL
deficiency. Firstly, the clinical and biochemical phenotype
of the proband is consistent with defective ABCA1, and
other possible causes of HDL deficiency were excluded.
Secondly, the two ABCA1 variants were not found in 164
alleles of English origin and, finally, both mutations were
found to disrupt trafficking to the plasma membrane of
ABCA1 protein when expressed in cultured cells in vitro.
Thus, the data are consistent with a diagnosis of HDL
deficiency caused by autosomal recessive defects in ABCA1.
Both L1379 and V1704 are conserved between human,
mouse and chicken ABCA1 and the regions in which they
lie are strongly conserved between ABCA1 and ABCA4
(formerly known as ABCR [35], Fig. 5). Simple Modular
Architecture Research Tool (SMART; http://www.smart.
embl-heidelberg.de) analysis predicts a secondary structure
consistent with that known for other ABC transporters, for
example P-glycoprotein, encoded by MDR1 [36], and the
bacterial lipid flippase MsbA [37]. ABCA1 is predicted to
consist of two tandem repeats, each comprising a trans-
membrane domain with six membrane-spanning segments
and an intracellular nucleotide binding domain. This topol-
ogy is supported by observations that FLAG or HA peptides
inserted in the extracellular loops of ABCA1 do not disrupt
its function and are accessible at the cell surface [38,39].
Fig. 5. Diagram showing alignment of human, murine and chicken ABCA1, and human ABCA1 and ABCA4. (a) Above, alignment of residues 1351–1409 of
human ABCA1 (NM_005502) with residues 1291–1349 of mouse (GenBank accession: NM_013454) and chicken ABCA1 (AF363377). Below, alignment of
the same residues of ABCA1 with residues 1377–1435 of human ABCA4 (NM_000350). The position of the L1379F substitution in ABCA1 is indicated in
bold; the residues predicted by Simple Modular Architecture Research Tool (SMART; http://www.smart.embl-heidelberg.de) analysis of the amino acid
sequence of ABCA1 to form membrane-spanning segment 7 in ABCA1 and ABCA4 are underlined. (b) Above, alignment of human, mouse and chicken
ABCA1 and below, human ABCA1 with human ABCA4, showing the position of the V1704D mutation in ABCA1 (indicated in bold). Residues predicted by
SMART to form membrane-spanning segment 9 in the carboxy-terminal half of ABCA1 and ABCA4 are underlined. (c) Diagram showing the predicted
topology of the carboxy-terminal half of ABCA1; membrane-spanning segments and the nucleotide binding domain (shaded oval) were predicted by SMART.
The two novel amino acid substitutions in the patient are indicated in bold; other single amino acid substitutions in the region in Tangier/HDL deficient
individuals are also shown (reviewed by Singaraja et al. [31]).
C. Albrecht et al. / Biochimica et Biophysica Acta 1689 (2004) 47–5754Despite these insights into ABCA1 structure, the molec-
ular mechanism for ABCA1-mediated cholesterol efflux is
still poorly understood [40]. Various models are proposed,
but each remains controversial, making it difficult to inter-
pret the structure–function relationship of the two new
mutations we describe. In our transfection studies both
mutants found in the patient clearly disrupted the trafficking
of the ABCA1 protein to the plasma membrane as visualised
by confocal microscopy. However, V1704 is predicted to liewithin membrane-spanning segment 9 and thus it is not
surprising that replacement of the hydrophobic valine res-
idue with negatively charged aspartate in this position
disrupts trafficking of the protein. Interestingly, only one
mutation in the first set of transmembrane segments of
ABCA1 (residues 636–908) has been observed previously
and none in the second set where V17104 is located. The
known mutant protein has a deletion of L693 from trans-
membrane segment 3 (equivalent to transmembrane seg-
C. Albrecht et al. / Biochimica et Biophysica Acta 1689 (2004) 47–57 55ment 9 in the carboxy-half of ABCA1), and also fails to be
transported from the ER [39].
The other amino acid substitution, L1379F, is predicted
to lie in the extracellular loop between transmembrane
segments 7 and 8 that may constitute the binding site for
apoAI [41]. This mutation predicts a relatively conserva-
tive substitution of one bulky hydrophobic residue for
another and it is less clear why it should disrupt trafficking
of ABCA1, but other amino acid substitutions in HDL
deficient patients have been found to lie in the same
predicted extracellular loop. Two of these, C1477R and
S1506L, do not appear to disrupt transport of the protein to
the cell surface, as judged by the accessibility of the
protein in non-permeabilised cells, but the mutant proteins
are unable to mediate cholesterol efflux [38]. However, the
subcellular localisation of these proteins was not visualised
by microscopy.
Skin fibroblasts from our proband contained approxi-
mately three times more ABCA1 mRNA than normal cells,
showing that the defect in ABCA1-mediated cholesterol
efflux resulted in up-regulation of the ABCA1 gene. There
was surprisingly little, less than 10%, variation in ABCA1
mRNA expression between different control cells. Prein-
cubation with cholesterol increased ABCA1 mRNA levels
in all cells, but more so in the patient’s cells. Despite this
difference in mRNA content, the amount of ABCA1
protein detected by Western blotting of membranes from
the proband’s or normal cells was similar. However, in
localisation studies we were able to demonstrate that,
although highly expressed, both mutant proteins display
markedly disrupted trafficking to the plasma membrane
suggesting severely impaired function. Failure of the mu-
tant ABCA1 proteins to reach the surface and bind apoAI
may also make them more susceptible to proteolytic
degradation [40,42].
Both the proband’s parents were alive and well at 80
years of age; clearly, the inheritance of both mutant alleles
of ABCA1 was necessary for the almost total HDL
deficiency and the unusually severe and progressive pre-
mature coronary disease seen in this female patient of 42
years. However, despite the almost complete absence from
plasma of HDL, there was no evidence of the cholesterol
accumulation in the liver, spleen or tonsils that is charac-
teristic of Tangier disease. Although Tangier patients
without all these clinical signs have been observed previ-
ously [5,43], there is currently no explanation for this
phenotypic variation. The relationship between particular
ABCA1 mutations, the reduction in HDL-cholesterol levels
and defective lipid efflux has been discussed in a recent
review [31], but why some Tangier disease patients have
obvious cholesterol deposition while others do not was not
raised. One possibility is suggested by emerging evidence
that ABCA1 also mediates intracellular trafficking of
substrate lipids, as well as of apoAI acceptor [44]. It is
tempting to speculate that the ABCA1 proteins in our
patient and that described by Bertolini et al. [43] retainsome residual intracellular function that somehow reduces
the cholesterol accumulation seen in macrophages in liver,
spleen or tonsils from Tangier patients with null alleles.Acknowledgements
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